Breast cancer is the most common cancer in women 1, and trastuzumab (Herceptin®, F. Hoffmann‐La Roche Ltd, Basel, Switzerland)‐containing regimens are standard of care for HER2‐positive disease 2, 3, 4. This evidence concerns the gene ERBB2 and breast carcinoma.